CytomX Therapeutics (CTMX) Cash from Financing Activities (2014 - 2026)

CytomX Therapeutics' Cash from Financing Activities history runs 13 years deep, the most recent figure standing at $234.5 million for Q1 2026.

• Quarterly Cash from Financing Activities changed N/A year-over-year to $234.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $344.9 million (up 4594.24% YoY) and the FY2025 annual result came in at $110.4 million, up 1368.31% from the prior year.
• Cash from Financing Activities was $234.5 million for Q1 2026 at CytomX Therapeutics, up from $16.6 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $234.5 million in Q1 2026 and bottomed at $7000.0 in Q1 2022.
• A 5-year average of $29.5 million and a median of $451000.0 in 2022 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 99.99% — and 2025, when it surged 1734.67%.
• CytomX Therapeutics' Cash from Financing Activities stood at $190000.0 in 2022, then rose by 28.42% to $244000.0 in 2023, then surged by 821.72% to $2.2 million in 2024, then surged by 640.02% to $16.6 million in 2025, then jumped by 1308.92% to $234.5 million in 2026.
• Business Quant data shows CTMX's Cash from Financing Activities at $234.5 million in Q1 2026, $16.6 million in Q4 2025, and $253000.0 in Q3 2025.